yingweiwo

Hydralazine

Alias: hydralazine; 1-Hydrazinylphthalazine; 1-Hydrazinophthalazine; 86-54-4; Hypophthalin;
Hydralazine is an orally bioactive anti-hypertensive (blood pressure lowering) drug that directly reduces peripheral resistance by relaxing the smooth muscle cell layer of arterial blood vessels.
Hydralazine
Hydralazine Chemical Structure CAS No.: 86-54-4
Product category: New1
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
5mg
10mg
50mg
100mg
Other Sizes

Other Forms of Hydralazine:

  • Hydralazine HCl (Apresoline, Adrolazine , Apresrex)
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Top Publications Citing lnvivochem Products
Product Description
Hydralazine is an orally bioactive anti-hypertensive (blood pressure lowering) drug that directly reduces peripheral resistance by relaxing the smooth muscle cell layer of arterial blood vessels. Hydralazine has anti-oxidant effect, inhibiting reactive oxygen species (ROS) release and O2·- generation, with IC50 of 9.53 mM and 1.19 mM respectively.
Hydralazine is a direct-acting vasodilator used for the treatment of hypertension and heart failure. It relaxes arterial smooth muscle by interfering with calcium transport, leading to reduced peripheral vascular resistance and lowered blood pressure. Hydralazine also functions as an antioxidant, inhibiting membrane-bound enzymes that form reactive oxygen species. It is used in combination with other antihypertensives, particularly in patients with heart failure and in hypertension associated with pregnancy. Hydralazine has a rapid onset of action and is available for oral, intramuscular, and intravenous administration. The compound also produces reflex tachycardia, which can be managed with beta-blockers. Hydralazine is on the World Health Organization’s List of Essential Medicines.
Biological Activity I Assay Protocols (From Reference)
Targets
The molecular mechanism of hydralazine involves interference with calcium transport in vascular smooth muscle cells. By altering cellular calcium metabolism, hydralazine prevents calcium influx and release from intracellular stores, thereby inhibiting smooth muscle contraction. The exact molecular target has not been definitively identified but may involve inhibition of inositol trisphosphate (IP3)-mediated calcium release or direct effects on calcium channels. Hydralazine also opens high-conductance calcium-activated potassium channels, contributing to vasodilation. Additionally, hydralazine functions as an antioxidant by inhibiting membrane-bound enzymes that form reactive oxygen species such as superoxides. This antioxidant activity may contribute to its cardiovascular protective effects.
ln Vitro
In vitro activity of hydralazine has been characterized using vascular smooth muscle cells and isolated blood vessels. In aortic ring preparations, hydralazine relaxes phenylephrine-induced contractions in a concentration-dependent manner. The vasorelaxant effect is endothelium-independent and is blocked by removal of extracellular calcium or by calcium channel blockers. In cultured vascular smooth muscle cells, hydralazine inhibits angiotensin II-induced calcium influx and reduces cell proliferation. It also inhibits superoxide production in endothelial cells and macrophages. Hydralazine shows no significant cytotoxicity in cell culture at concentrations up to 100 µM.
ln Vivo
In vivo activity of hydralazine has been extensively characterized in animal models of hypertension and heart failure. In spontaneously hypertensive rats, hydralazine reduces systolic and diastolic blood pressure in a dose-dependent manner. In heart failure models, hydralazine improves cardiac output and reduces afterload. In pregnancy-induced hypertension models, hydralazine lowers blood pressure without compromising uteroplacental blood flow. Hydralazine also reduces oxidative stress markers in tissues. Pharmacokinetic studies indicate that hydralazine has rapid oral absorption and a plasma half-life of 2–4 hours. It undergoes acetylation in the liver, and acetylation status affects bioavailability.
Enzyme Assay
In vitro assays for hydralazine include vascular reactivity studies using isolated aortic rings and calcium flux measurements in smooth muscle cells. For aortic ring experiments, rings are mounted in tissue baths, and isometric tension is recorded. Hydralazine is added cumulatively after pre-contraction with phenylephrine. For calcium flux assays, cells are loaded with Fura-2 or Fluo-4 and stimulated with agonists in the presence or absence of hydralazine. Superoxide production is measured using lucigenin-enhanced chemiluminescence or dihydroethidium staining. All assays include appropriate controls.
Cell Assay
In vitro cell experiments with hydralazine use vascular smooth muscle cells, endothelial cells, or cardiac fibroblasts. Cells are cultured in standard media and treated with hydralazine at concentrations ranging from 1 to 100 µM. Proliferation is assessed by MTT or BrdU incorporation. Calcium signaling is measured using fluorescent indicators. Superoxide production is measured by DHE staining or lucigenin assay. Apoptosis is assessed by caspase-3 activity or annexin V staining. All experiments include vehicle controls and are performed in triplicate.
Animal Protocol
In vivo animal experiments with hydralazine use rats or mice. Hydralazine is dissolved in saline and administered by oral gavage, intraperitoneal injection, or intravenous infusion at doses ranging from 1 to 20 mg/kg. Blood pressure is measured by tail-cuff plethysmography or intra-arterial catheterization. For heart failure models, cardiac function is assessed by echocardiography. For pregnancy studies, uterine blood flow is measured. Tissues are harvested for oxidative stress markers and histopathology. All procedures follow institutional animal care guidelines.
ADME/Pharmacokinetics
Absorption, Distribution and Excretion
Oral administration of hydralazine with food improves its bioavailability. After intravenous injection of 0.3 mg/kg, the AUC is 17.5-29.4 µMmin; after oral administration of 1 mg/kg, the AUC is 4.0-30.4 µMmin. The Cmax of oral hydralazine is 0.12-1.31 µM, depending on the patient's acetylation status. 10% of hydralazine is excreted in feces; 65-90% is excreted in urine. The volume of distribution is 1.34 ± 0.79 L/kg in patients with congestive heart failure and 1.98 ± 0.22 L/kg in patients with hypertension. The clearance of hydralazine primarily occurs extrahepatically—55% in patients with rapid acetylation and 70% in patients with slow acetylation. The mean clearance rate in patients with congestive heart failure was 1.77 ± 0.48 L/kg/h, while the mean clearance rate in hypertensive patients was 42.7 ± 8.9 mL/min/kg. Metabolism/Metabolites Acetylation is a minor metabolic pathway for hydralazine; the major metabolic pathway is hydroxylation, followed by glucuronidation. Five metabolic pathways for hydralazine have been identified. Hydralazine can be metabolized to phthalazine or α-ketoglutarate hydrazone. These metabolites can be further converted to phthalazinones, or hydralazine can be directly metabolized to phthalazinones. Hydralazine can be reversibly converted to the active product hydralazine-acetylasinone. Hydralazine can spontaneously convert to the active product pyruvate hydrazone or its tricyclic dehydration product; these metabolites can interconvert between these two forms. Hydralazine can be converted to hydrazylphthalazinone, which can be further converted to the active product acetylhydrazylphthalazinone. The final metabolic pathway of hydralazine involves conversion to an unnamed hydralazine metabolite, which is further metabolized to 3-methyltriazolamide (MTP). MTP can be metabolized to 9-hydroxymethyltriazolamide or 3-hydroxymethyltriazolamide; the latter can be converted to triazolamide. Known metabolites of hydralazine include the N-acetyl group. The half-life of hydralazine is 2.2–7.8 hours in rapid acetylated individuals and 2.0–5.8 hours in slow acetylated individuals. In patients with heart failure, the half-life of hydralazine is 57–241 minutes, with an average of 105 minutes; in hypertensive patients, the half-life is 200 minutes in rapid acetylated individuals and 297 minutes in slow acetylated individuals. Hydralazine exhibits polymorphic acetylation; slow acetylated individuals typically have higher plasma concentrations of hydralazine, thus requiring lower doses to control blood pressure. However, other factors, such as acetylation, which is a secondary metabolic pathway of hydralazine, can also lead to differences in elimination rates.
Toxicity/Toxicokinetics
Hepatotoxicity
Elevated serum transaminases are uncommon during hydralazine treatment. However, hydralazine has been definitively linked to acute liver injury with jaundice and delayed lupus-like syndrome. Two clinical patterns of liver injury have been described, associated with short latency periods (2 to 6 weeks) or long latency periods (2 months to over a year). Clinically apparent liver injury is usually hepatocellular, but cholestatic patterns have also been reported (Case 1). In short-latency cases, rash, fever, and eosinophilia are common; onset is typically abrupt and severe, but recovery is rapid. In long-latency cases (Case 2), onset is usually more insidious; liver biopsy may resemble chronic hepatitis and show fibrosis, and autoantibodies are often present. Late-stage hepatitis may also be accompanied by lupus-like syndrome induced by hydralazine, especially with high-dose use for 6 months or longer. Recovery may be prolonged. In patients with hepatotoxicity caused by the structure-related antihypertensive drug dihydrozirconium (available in Europe but not in the US), autoantibodies against the P450 system (CYP 1A2) isoenzyme have been identified, and the incidence of hepatotoxicity with dihydrozirconium is higher than with hydralazine.
Probability score: A (Etiology of clinically confirmed liver injury).
Pregnancy and lactation effects
◉ Overview of use during lactation
Limited data on milk and infant serum concentrations, along with a long history of use in postpartum mothers, suggest that hydralazine is an acceptable antihypertensive drug for lactating mothers, including mothers of newborns.
◉ Effects on breastfed infants
No adverse reactions were reported in an 8-week-old breastfed infant.
◉ Effects on lactation and breast milk
No relevant published information found. Found as of the revision date.
Protein binding
hydralazine has a protein binding rate of 87% in serum and may bind to human serum albumin.
References

[1]. Arce C, Segura-Pacheco B, Perez-Cardenas E, Taja-Chayeb L, Candelaria M, Dueñnas-Gonzalez A. Hydralazine target: from blood vessels to the epigenome. J Transl Med. 2006 Feb 28;4:10.

[2]. Antioxidant activity and inhibitory effects of hydralazine on inducible NOS/COX-2 gene and protein expression in rat peritoneal macrophages. Int Immunopharmacol. 2004 Feb;4(2):163-77.

Additional Infomation
Hydralazine is a 1-hydrazine derivative of phthalazine, a direct-acting vasodilator used as an antihypertensive drug. It is both an antihypertensive and a vasodilator. Hydralazine belongs to the phthalazine, aza-aromatic, ortho-fused aza-aromatic, and hydrazine classes. Initially developed in the 1950s for the treatment of malaria, hydralazine quickly demonstrated antihypertensive effects and was repurposed for treating other diseases. Hydralazine is a hydrazine derivative vasodilator that can be used alone or as adjunctive therapy for hypertension, but only as adjunctive therapy for heart failure. With the advent of newer antihypertensive drugs, hydralazine is no longer a first-line treatment for these diseases. Hydralazine hydrochloride was approved by the U.S. Food and Drug Administration (FDA) on January 15, 1953. Hydralazine is a small artery vasodilator. Its physiological action is achieved by dilating small arteries. Hydralazine is a commonly used oral antihypertensive drug whose mechanism of action is through inducing peripheral vasodilation. Hydralazine is associated with various acute liver injuries and lupus-like syndromes. Hydralazine has been reported in Achillea pseudopectinata, and relevant data are available. Hydralazine is an phthalazine derivative with antihypertensive effects. It exerts its vasodilatory effect by altering the contractile state of arterial smooth muscle, thereby changing intracellular calcium release and interfering with calcium influx into smooth muscle cells. This drug can also inhibit myosin phosphorylation or chelate trace metals required for smooth muscle contraction, thereby increasing heart rate, stroke volume, and cardiac output. It is a direct-acting vasodilator used as an antihypertensive drug. See also: hydralazine hydrochloride (salt form). Drug Indications Hydralazine can be used alone or as adjunctive therapy for the treatment of essential hypertension. Combination formulations with isosorbide dinitrate can be used as adjunctive therapy for the treatment of heart failure. Mechanism of Action Hydralazine may relax arteriole smooth muscle and lower blood pressure by interfering with calcium transport in vascular smooth muscle through an unknown mechanism. Interference with calcium transport may be achieved by preventing calcium inflow into cells, preventing calcium release from cells, acting directly on actin and myosin, or a combination of these actions. The reduction in vascular resistance leads to an increase in heart rate, stroke volume, and cardiac output. Hydralazine also competes with procollagen prolyl hydroxylase (CPH) for free iron. This competition inhibits CPH-mediated HIF-1α hydroxylation, thereby preventing HIF-1α degradation. Induction of HIF-1α and VEGF promotes endothelial cell proliferation and angiogenesis. Pharmacodynamics Hydralazine relaxes arteriole smooth muscle and lowers blood pressure by interfering with calcium ion transport. The duration of action of hydralazine is short, ranging from 2 to 6 hours. It has a wide therapeutic window, and patients can tolerate doses up to 300 mg. Patients should be informed of the risk of developing systemic lupus erythematosus syndrome.
These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C8H8N4
Molecular Weight
160.17592
Exact Mass
160.075
CAS #
86-54-4
Related CAS #
Hydralazine hydrochloride;304-20-1
PubChem CID
3637
Appearance
White to off-white solid
Density
1.2583 (rough estimate)
Boiling Point
276.07°C (rough estimate)
Melting Point
172ºC
Index of Refraction
1.5872 (estimate)
LogP
1.688
tPSA
63.83
Hydrogen Bond Donor Count
2
Hydrogen Bond Acceptor Count
4
Rotatable Bond Count
1
Heavy Atom Count
12
Complexity
150
Defined Atom Stereocenter Count
0
SMILES
N(=C1C2C(=CC=CC=2)C=NN1)N
InChi Key
RPTUSVTUFVMDQK-UHFFFAOYSA-N
InChi Code
InChI=1S/C8H8N4/c9-11-8-7-4-2-1-3-6(7)5-10-12-8/h1-5H,9H2,(H,11,12)
Chemical Name
phthalazin-1-ylhydrazine
Synonyms
hydralazine; 1-Hydrazinylphthalazine; 1-Hydrazinophthalazine; 86-54-4; Hypophthalin;
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
DMSO: ~20 mg/mL (~124.9 mM; with ultrasonication and warming by heating to 60°C)
Solubility (In Vivo)
Solubility in Formulation 1: ≥ 2 mg/mL (12.49 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (20.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

Solubility in Formulation 2: ≥ 2 mg/mL (12.49 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (20.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well.
Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 6.2430 mL 31.2149 mL 62.4298 mL
5 mM 1.2486 mL 6.2430 mL 12.4860 mL
10 mM 0.6243 mL 3.1215 mL 6.2430 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration: mg/mL;

Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Clinical Trial Information
A Phase 1 Single Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Oral Hydralazine in Healthy Volunteers
CTID: NCT00311974
Phase: Phase 1
Status: Completed
Date: 2010-02-18
Randomized Controlled Trial of Hydralazine Plus Isosorbide Dinitrate for Heart Failure in Self-Identified Black Patients (V-HeFT III)
CTID: NCT00000478
Phase: Phase 3
Status: Completed
Date: 1995-03-21
Multicenter Trial of Intravenous Hydralazine for Acute Severe Hypertension in Pregnancy
CTID: Not Applicable
Phase: Phase 3
Status: Completed
Date: 2007-11-05
Randomized Trial Comparing Hydralazine and Labetalol for Hypertensive Emergencies During Pregnancy
CTID: NCT01225344
Phase: Phase 3
Status: Completed
Date: 2010-10-28
Long-Term Phase 4 Observational Study on the Safety of Chronic Hydralazine Treatment and Risk of Drug-Induced Lupus Erythematosus
CTID: NCT03974968
Phase: Phase 4
Status: Completed
Date: 2019-05-14
Pharmacogenomic Study Evaluating the Impact of NAT Genotype on Hydralazine Pharmacokinetics and Adverse Reactions
CTID: Not Applicable
Phase: Phase 1
Status: Completed
Date: 2021-04-09
Contact Us